Galera Therapeutics, Inc. Form 8-K Filing

On April 7, 2026, Galera Therapeutics, Inc. converted 76,479,175 shares of its Series B Non-Voting Convertible Preferred Stock into 76,479,164 shares of its common stock. Fractional shares were not issued; instead, cash payments will be made for any fractional amounts. Following this conversion, 42,839.11 shares of Series B Preferred Stock remain outstanding. Additionally, on April 8, 2026, affiliates of Ikarian Capital, LLC exercised pre-funded warrants to purchase 8,488,229 shares of common stock at $0.001 per share, with the exercise price of approximately $8,488.23 paid to the company. Pre-funded warrants for an additional 14,552,811 shares of common stock remain outstanding.